Concepedia

Michael Sangi

MS

6

Publications

421

Citations

6

H-Index

2013

Active since

Affiliations

Gilead Sciences (United States)(Current)

La Roche College

Baylor College of Medicine

Michael Sangi is an author at Gilead Sciences (United States) specializing in medicine, virology, and drug discovery.

Top concepts

Publications per year

2013–2019

6

Publications

6

Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study

Richard L. Mackman, Michael Sangi, David Sperandio et al. · Journal of Medicinal Chemistry · 2015 · 120 citations

, , +12

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®

James G. Taylor, Sheila Zipfel, Kyla Ramey et al. · Bioorganic & Medicinal Chemistry Letters · 2019 · 83 citations

, , +6

GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process

Michel Perron, Kirsten M. Stray, April Kinkade et al. · Antimicrobial Agents and Chemotherapy · 2015 · 77 citations · Full text

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle

Richard L. Mackman, Victoria A. Steadman, David K. Dean et al. · Journal of Medicinal Chemistry · 2018 · 75 citations · Full text

Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B

Ryan C. Schoenfeld, David L. Bourdet, Ken A. Brameld et al. · Journal of Medicinal Chemistry · 2013 · 36 citations · Full text

, , +16

Rows per page

1–5 of 6